

Welcome to our exciting symposium on precision cancer medicine in Helsinki!
Registration OPEN deadline 4.9.22
Abstract submission OPEN deadline 12.6.22
The two-day meeting will also have a poster session and social activities.
Confirmed speakers with tentative titles:
THURSDAY, SEPTEMBER 22
Keynotes/Special Lectures:
Kari Alitalo, University of Helsinki
TBC
Peter Kraft, Harvard University:
Polygenic risk scores and tailored cancer screening
Pasi Jänne, Dana-Farber Cancer Institute, Harvard Medical School:
Beyond the magic bullet
SESSIONS 1-3
Christian Meisel, Hedera Dx:
Actionable ctDNA based insights for precision cancer medicine
Jesus Banales, Biodonostia:
Genetic background of primary sclerosing cholangitis associated cholangiocarcinoma (PSC-CCA)
Cyriel Ponsioen, Amsterdam AMC:
Primary sclerosing cholangitis (PSC) dysplasia surveillance
Daniel Peeper, Netherlands Cancer Institute:
Rational concepts for tumor & immune cell therapy combinations
Marco Gerlinger, ICR The Institute of Cancer Research
TBC
Johanna Ivaska, University of Turku:
Stromal barriers to cancer progression
Francesca M. Buffa, University of Oxford:
Machine Learning and Systems Biology approaches in Precision Oncology
Pekka Katajisto, University of Helsinki:
NOTUM from Apc-mutant cells biases clonal competition to initiate cancer
FRIDAY SEPTEMBER 23
Keynotes/Special Lectures:
Bettina Ryll, Melanoma Patient Network Europe:
From good to great: What patients can do for your research?
SESSIONS 4-6
Karin de Visser, Netherlands Cancer Institute:
Innate-adaptive immune cell crosstalk dictates response to immune checkpoint blockade in breast cancer
Giulio Superti-Furga, CeMM, Medical University of Vienna:
Precision pharmacology and metabolic modulation in hematologic cancers
Kjetil Taskén, Institute of Cancer Research, Oslo University Hospital:
A national precision cancer medicine implementation initiative for Norway
Lynette Sholl, Brigham and Women’s Hospital/Harvard Medical School:
Molecular diagnostics of cancer to support individualized therapy: perspectives from a clinical lab
Prasad Adusumilli, Memorial Sloan Kettering Cancer Center:
CAR-T cell therapy for solid tumors; new opportunities and challenges
Åslaug Helland, Oslo University Hospital:
Personalized medicine in thoracic oncology; where are we now and where we are going – where we have the most to gain?
Dario Campana, NUS Yong Loo Lin School of Medicine:
Disrupting the treatment of lymphoid malignancies with CAR-T cells
Maria Themeli, Amsterdam UMC:
Designing optimal dual-targeting of CAR T cells: the BETTER gate
Satu Mustjoki, University of Helsinki:
Mechanisms of natural killer cell immune evasion by functional immune profiling
Organising committee:
Johanna Arola, chair
Tomi Mäkelä, vice chair
Caroline Heckman
Päivi Ojala
Sirpa Leppä
Ilkka Ilonen
Secretariat:
Tiina Vesterinen, FCI
Leena Karhinen, iCAN
Satu Sankkila, iCAN
Saija Piiroinen, iCAN
Contact: ican-fci@helsinki.fi